On November 5, 2023, the Board of Directors (the board) of Harmony Biosciences Holdings, Inc. increased the size of the Board from nine to ten directors and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company's 2026 annual meeting of stockholders, effective immediately. The board also appointed Mr. Anastasiou to serve as a member of the Compensation Committee of the Board. Mr. Anastasiou, age 53, has served as Chief Executive Officer and as a member of the board of directors of Capsida Biotherapeutics, a next-generation integrated gene therapy company, since January 2022.

Prior to Capsida, from November 2009 to December 2021, Mr. Anastasiou served in various roles at Lundbeck, a pharmaceutical company publicly traded on the Copenhagen Stock Exchange, including most recently as Executive Vice President and President of North America, and prior to that as Chief Commercial Officer for the U.S. and Vice President and General Manager for Psychiatry. In addition, he served as a member of the board of directors of Lundbeck from January 2016 to December 2021. Mr. Anastasiou currently serves on the Global Advisory Board of the Healthcare Businesswomen's Association and has previously served on the boards of several private organizations, including the Pharmaceutical Research and Manufacturers Association (PhRMA), Kids Above All and Bear Necessities Pediatric Cancer Foundation.

Mr. Anastasiou received a B.A. in Economics and Management from Albion College and an M.B.A. from Kelley School of Business, Indiana University. The company believe that Mr. Anastasiou is qualified to serve on its Board because of his extensive experience in the life sciences industry developing and leading multifaceted biotechnology organizations, as well as his demonstrated business acumen.